The effect of cannabis on the appetite in cancer patients

The effect of cannibinols in patients with pancreatic cancer in the palliative state - Cannibinols in cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-000530-54-DK

Enrollment

Registered

2017-03-15

Start date

2018-01-16

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer MedDRA version: 20.1 Level: LLT Classification code 10037027 Term: Protein-calorie malnutrition System Organ Class: 100000004861 MedDRA version: 20.0 Level: LLT Classification code 10064015 Term: Cancer cachexia System Organ Class: 100000004861 MedDRA version: 20.0 Level: LLT Classification code 10033604 Term: Pancreatic cancer System Organ Class: 100000004864

Interventions

Product Name: Dronnabinol oral administration 25mg/ml Pharmaceutical Form: Oral drops INN or Proposed INN: DRONABINOL CAS Number: 1972-08-3 Concentration unit: mg/ml milligram(s)/millilitre Concentrat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult. Palliative pancreas cancer diagnosis Weightloss more than 5% Understand and read Danish Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 22

Exclusion criteria

Exclusion criteria: Use of cannabis at baseline Psychiatric diagnosis Alcohol abuse

Design outcomes

Primary

Measure	Time frame
Main Objective: Improve appetite and nutritional status in patients;Secondary Objective: Not applicable;Primary end point(s): Intake of protein and energy;Timepoint(s) of evaluation of this end point: 0, 2, 4, 6, and 8 weeks	—

Secondary

Measure	Time frame
Secondary end point(s): Lean body mass (Bio-impedance) Quality of life Appetite (VAS) Pain (VAS) Mortality;Timepoint(s) of evaluation of this end point: 0, 2, 4, 6, and 8 weeks	—

Countries

Denmark

Contacts

Public ContactUniversity of Copenhagen, Departmen

University of Copenhagen, Department of Nutrition, Exercise and Sports

jra@nexs.ku.dk004523346654

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026